Physician profile
Ramesh C Misra
NPI 1912975442
$4,007.25
in general payments reported to CMS, 2019-2025
36 companies · $225 in 2025
The $225 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $740 · 2021: $1,034 · 2022: $975 · 2023: $407 · 2024: $23.24 · 2025: $225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $655.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $606.42 | 2019-2022 | |
| Abbott Laboratories | $554.65 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $399.66 | 2019-2025 | Lifevest |
| Amgen INC. | $272.19 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $245.15 | 2019-2022 | |
| Abiomed | $203.09 | 2023-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $160.96 | 2020-2022 | |
| Edwards Lifesciences Corporation | $147.05 | 2019-2025 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $142.72 | 2019-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $123.58 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $115.61 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $112.52 | 2020-2022 | |
| Astellas Pharma US INC | $109.70 | 2019-2022 | |
| Pfizer INC. | $106.66 | 2019-2022 | |
| Cordis US Corp. | $87.46 | 2024-2025 | Mynx Control Venous, Mynx Venous Vcd |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $72.08 | 2022 | |
| Heartflow, INC. | $67.10 | 2019-2022 | |
| Esperion Therapeutics, INC. | $66.53 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.05 | 2019-2022 | |
| Kestra Medical Technology Services, INC. | $42.29 | 2022 | |
| Philips North America LLC | $32.61 | 2019-2021 | |
| Alnylam Pharmaceuticals INC. | $28.90 | 2021 | |
| Arbor Pharmaceuticals, INC. | $27.49 | 2020 | |
| Bardy Diagnostics, INC. | $25.37 | 2021-2022 | |
| Amarin Pharma, INC. | $23.78 | 2022 | |
| Vifor Pharma, INC. | $22.57 | 2019 | |
| Ethicon US, LLC | $19.98 | 2021 | |
| Medtronic Vascular, INC. | $18.54 | 2019 | |
| Boston Scientific Corporation | $17.53 | 2022 | |
| Lundbeck LLC | $15.71 | 2021 | |
| Genzyme Corporation | $15.64 | 2019 | |
| Amryt Pharma Holdings LTD | $15.05 | 2021 | |
| Bard Peripheral Vascular, INC. | $14.51 | 2023 | Crosser Iq |
| Cardinal Health 200 LLC | $13.97 | 2021 | |
| United Therapeutics Corporation | $12.67 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $12.46 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Misra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.